GlassScriptPhysician profile
Ruben J Ayala
NPI 1326012303
$24,219.07
in general payments reported to CMS, 2019-2025
61 companies · $3,333 in 2025
The $3,333 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,811 · 2020: $2,791 · 2021: $4,284 · 2022: $2,176 · 2023: $3,232 · 2024: $3,592 · 2025: $3,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,977 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,977.25 |
| Education | $180.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,428.25 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,922.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,853.99 | 2019-2025 | Ubrelvy, Viberzi, Linzess |
| Sanofi-Aventis U.S. LLC | $1,729.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,509.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $1,375.99 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $966.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $916.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $909.80 | 2019-2025 | Synjardy, Jardiance, Ofev |
| Esperion Therapeutics, INC. | $874.87 | 2020-2025 | Nexletol |
| Shield Therapeutics INC | $688.17 | 2022-2025 | Accrufer |
| Astellas Pharma US INC | $672.14 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $659.30 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $644.83 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $570.20 | 2021-2025 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $549.65 | 2020-2024 | Amplatzer Talisman, Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $432.76 | 2019-2024 | Xarelto |
| Pfizer INC. | $419.34 | 2019-2025 | |
| Inspire Medical Systems, INC. | $382.50 | 2024 | Inspire |
| Exact Sciences Corporation | $344.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Radius Health, INC. | $335.84 | 2019-2021 | |
| Allergan, INC. | $314.95 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $291.16 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $285.38 | 2019-2023 | Verquvo, Lagevrio, Belsomra |
| Sunovion Pharmaceuticals INC. | $230.40 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $213.19 | 2021-2023 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $181.83 | 2019-2024 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $180.18 | 2019-2025 | Zoryve |
| Azurity Pharmaceuticals, INC. | $162.66 | 2023-2024 | Horizant, Horizant |
| Eisai INC. | $154.03 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $147.12 | 2020-2021 | |
| Optinose US, INC. | $145.68 | 2019-2025 | |
| Biogen, INC. | $144.53 | 2021 | |
| Impulse Dynamics (USA) INC. | $142.93 | 2022 | |
| Horizon Therapeutics Plc | $141.19 | 2019-2021 | |
| Insulet Corporation | $119.42 | 2021-2025 | Omnipod |
| Ardelyx, INC. | $118.95 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $118.00 | 2023-2024 | Watchman Flx |
| Insmed, INC. | $96.45 | 2025 | Brinsupri, Arikayce |
| Corcept Therapeutics | $96.08 | 2021-2025 | Korlym |
| Smith+Nephew, INC. | $88.15 | 2019-2025 | Collagenase Santyl |
| Ironwood Pharmaceuticals, INC | $84.96 | 2021 | |
| Dexcom, INC. | $56.10 | 2024-2025 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $53.89 | 2023-2025 | Gimoti |
| Scilex Pharmaceuticals INC. | $45.53 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $39.48 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $37.03 | 2019-2025 | Evkeeza |
| Cipher Pharmaceuticals US LLC | $36.47 | 2025 | Spinosad, Natroba |
| Sumitomo Pharma America, INC. | $35.70 | 2025 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $34.04 | 2021 | |
| Mannkind Corporation | $33.30 | 2019 | |
| Nabriva Therapeutics, Plc | $31.96 | 2021 | |
| Aimmune Therapeutics, INC. | $27.10 | 2025 | Zenpep |
| Ultragenyx Pharmaceutical INC. | $22.01 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.79 | 2024 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $19.80 | 2022 | |
| Ibsa Pharma INC. | $19.33 | 2024 | Licart, Tirosint |
| Gilead Sciences, INC. | $19.32 | 2023 | |
| Axsome Therapeutics, INC. | $15.00 | 2025 | Auvelity |
| Hikma Pharmaceuticals USA | $13.67 | 2023 | Mitigare, Ryaltris, Kloxxado |
| Avanir Pharmaceuticals, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.